Again in 2020, Yu et al. performed a cross-sectional case-control study on 42 women with non-metastatic ERBB2-positive breast cancer who completed trastuzumab-based therapy, at least 2 years before study entry, with 38 of 42 patients (90%) were treated with anthracyclines before trastuzumab. Here, ERBB2 is linked to breast cancer.